$5.62
6.34% yesterday
Nasdaq, Nov 25, 09:24 pm CET
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Molecular Partners AG - ADR Stock price

$5.62
-0.87 13.41% 1M
+1.82 47.89% 6M
+1.44 34.45% YTD
+1.22 27.73% 1Y
-5.62 50.00% 3Y
-15.38 73.24% 5Y
-15.38 73.24% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.33 6.34%
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Key metrics

Market capitalization $207.17m
Enterprise Value $40.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.91
P/S ratio (TTM) P/S ratio 30.47
P/B ratio (TTM) P/B ratio 1.13
Revenue growth (TTM) Revenue growth -27.94%
Revenue (TTM) Revenue $6.80m
EBIT (operating result TTM) EBIT $-71.40m
Free Cash Flow (TTM) Free Cash Flow $-65.74m
Cash position $170.25m
EPS (TTM) EPS $-2.15
P/E forward negative
P/S forward 33.15
EV/Sales forward 6.43
Short interest 0.22%
Show more

Is Molecular Partners AG - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Molecular Partners AG - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Molecular Partners AG - ADR forecast:

3x Buy
60%
2x Hold
40%

Analyst Opinions

5 Analysts have issued a Molecular Partners AG - ADR forecast:

Buy
60%
Hold
40%

Financial data from Molecular Partners AG - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6.80 6.80
28% 28%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
8% 8%
223%
- Research and Development Expense 58 58
10% 10%
847%
-69 -69
11% 11%
-1,010%
- Depreciation and Amortization 2.72 2.72
3% 3%
40%
EBIT (Operating Income) EBIT -71 -71
10% 10%
-1,050%
Net Profit -71 -71
9% 9%
-1,042%

In millions USD.

Don't miss a Thing! We will send you all news about Molecular Partners AG - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Molecular Partners AG - ADR Stock News

Neutral
GlobeNewsWire
19 days ago
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only
Neutral
GlobeNewsWire
26 days ago
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025
Neutral
GlobeNewsWire
about one month ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the pricing of an underwritten offering in the ...
More Molecular Partners AG - ADR News

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Patrick Amstutz
Employees 182
Founded 2004
Website www.molecularpartners.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today